Pharmaceutical Investing Zealand Pharma Doses First Patient in Phase 3 Trial with Dasiglucagon for Treatment of Congenital Hyperinsulinism
Pharmaceutical Investing Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
